Cervix Cancer A GCIG Perspective Keiichi Fujiwara, MD, PhD Saitama - - PowerPoint PPT Presentation

▶
cervix cancer
SMART_READER_LITE
LIVE PREVIEW

Cervix Cancer A GCIG Perspective Keiichi Fujiwara, MD, PhD Saitama - - PowerPoint PPT Presentation

Jul 17, 2023 250 likes •423 views

Gynecologic Cancer InterGroup Cervix Cancer Research Network Cervix Cancer A GCIG Perspective Keiichi Fujiwara, MD, PhD Saitama Medical University International Medical Center, Japan GCIG Chair Cervix Cancer Education Symposium, January

slide-1
SLIDE 1

Cervix Cancer A GCIG Perspective

Keiichi Fujiwara, MD, PhD

Saitama Medical University International Medical Center, Japan GCIG Chair

Cervix Cancer Education Symposium, January 2019, South Africa

Gynecologic Cancer InterGroup Cervix Cancer Research Network

slide-2
SLIDE 2

Gynecologic Cancer InterGroup Cervix Cancer Research Network

Cervical Cancer

  • Second most common cancer among women worldwide.
  • Second most common cause of cancer-related mortality

in women globally.

  • Human papillomavirus (HPV) infections are the cause of

nearly all cervical cancers.

  • Preventable through screening and vaccination

Cervix Cancer Education Symposium, January 2019, South Africa

slide-3
SLIDE 3

Estimated Age-Standardised rates per 100,000 ✓ Globocan 2012 - WHO

A Prototype: Estimated Cervical Cancer Mortality Worldwide

slide-4
SLIDE 4

Gynecologic Cancer InterGroup Cervix Cancer Research Network

Cervix Cancer Education Symposium, January 2019, South Africa

GLOBOCAN 2018, WHO

slide-5
SLIDE 5

Gynecologic Cancer InterGroup Cervix Cancer Research Network

Cervical Cancer

  • Second most common cancer among women worldwide.
  • Second most common cause of cancer-related mortality

in women globally.

  • Human papillomavirus (HPV) infections are the cause of

nearly all cervical cancers.

  • Preventable through screening and vaccination
  • If not prevented

– Early Stage Disease: Surgery – Locally Advanced Disease: Chemoradiation – Metastatic Disease: Chemotehrapy

Cervix Cancer Education Symposium, January 2019, South Africa

slide-6
SLIDE 6

Gynecologic Cancer InterGroup Cervix Cancer Research Network

Research Questions for Cervical Cancer

  • For Early Stage Disease

– ? Less invasive surgery improves QOL without compromise survival

  • For Locally Advanced Disease

– ? Addition of Adjuvant Chemotherapy to CRT improves survival – ? Combination of Immunotherapy improves survival

  • For Metastatic Disease

– ? Combination of antiangiogenics improves survival – ? Combination of Immunotherapy improves survival

Cervix Cancer Education Symposium, January 2019, South Africa

slide-7
SLIDE 7

Gynecologic Cancer InterGroup Cervix Cancer Research Network

To Obtain Answers to the Research Questions for Cervical Cancer

  • Clinical Trials is inevitable!

Cervix Cancer Education Symposium, January 2019, South Africa

slide-8
SLIDE 8

bradley.monk@chw.edu

Progress in Survival in Advanced and Recurrent Cervical Cancer

Months Year

GOG 64 Cisplatin

  

GOG 179 Cisplatin + Palcitaxel + Bevacizumab

slide-9
SLIDE 9

Gynecologic Cancer InterGroup Cervix Cancer Research Network

To Obtain Answers to the Research Questions for Cervical Cancer

  • Clinical Trials is inevitable with

– Multidisciplinary – Multicenter – International

Collaboration

GCIG

Cervix Cancer Education Symposium, January 2019, South Africa

slide-10
SLIDE 10

Gynecologic Cancer InterGroup Cervix Cancer Research Network

Cervix Cancer Education Symposium, January 2019, South Africa

https://gciggroup.com/

slide-11
SLIDE 11

Gynecologic Cancer InterGroup Cervix Cancer Research Network

Cervix Cancer Education Symposium, January 2019, South Africa

  • Mission Statement:

– The Gynecological Cancer InterGroup aims to promote and facilitate high quality clinical trials in order to improve outcomes for women with gynecological cancer.

https://gciggroup.com/

slide-12
SLIDE 12

Gynecologic Cancer InterGroup Cervix Cancer Research Network

Cervix Cancer Education Symposium, January 2019, South Africa

  • Vision Statement:

– Improving quality and duration of life for women with gynecologic cancers will be accomplished through a focused common purpose, shared expertise, and mutual respect among members, and with recognition and accommodation of cultural, geographic, and clinical diversities amongst and between members and patients.

https://gciggroup.com/

slide-13
SLIDE 13

GCIG

Current Situation

  • Currently 32 groups are GCIG members.

– 16 Europe – 7 US and Canada – 6 ASIA – 1 Australia/New Zealand – 2 Latin America – 0 Africa

www.gciggroup.com

slide-14
SLIDE 14
  • r many others

Countries represented in the GCIG future?

www.gciggroup.com

640 million people >1.800 million

slide-15
SLIDE 15

Gynecologic Cancer InterGroup Cervix Cancer Research Network

Summary

  • Incidence of cervical cancer is extremely higher

in developing countries.

  • Therefore, it is strategically important to get the

involvement of those countries for the development of new therapies.

  • GCIG is now playing an major role to conduct

clinical trials for cervical cancer in those countries in collaboration with CCRN.

Cervix Cancer Education Symposium, January 2019, South Africa

slide-16
SLIDE 16

Gynecologic Cancer InterGroup Cervix Cancer Research Network

Cervix Cancer Education Symposium, January 2019, South Africa